TABLE 2.
UPCs in CMHS and ER during the two observation periods: setting and clinical activities.
| Variables | Pre-COVID-19 period: UPCs in CMHS (n = 1,162) ER (n = 1,194) | COVID-19 period: UPCs in CMHS (n = 1,214) ER (n = 909) | Statistical test probability |
| UPCs in CMHS: Setting, n (%) | |||
| CMHS | 1006 (86.6%) | 900 (74.1%)* | χ2 = 83.95 p = 0.000 *SR = −7.57 **SR = 3.03 ***SR = 8.23 |
| Home patient | 67 (5.8%) | 81 (6.7%) | |
| Video call | 62 (5.3%) | 103 (8.5)** | |
| Telephone call | 25 (2.2%) | 126 (10.4%)*** | |
| UPCs in CMHS: Therapy administration, n (%) | |||
| Drugs administered | 832 (72%) | 708 (58%) | χ2 = 52.38 p = 0.001 |
| No drugs administered | 330 (28%) | 506 (42%) | |
| UPCs in ER: Supplementary diagnostic test and/or additional medical consultations, n (%) | |||
| Not required | 1057 (87.9%) | 791 (87%) | Not statistically significant |
| Required | 137 (12.1%) | 118 (13%) | |
| UPCs in ER: Short –Stay observation | |||
| Not applied | 1050 (87.9%) | 806 (89.4%) | Not statistically significant |
| Applied | 144 (12.1%) | 96 (10.6%) | |
| UPCs in ER: Therapy prescription and/or administration | |||
| No therapy prescription and/or administration | 584 (49.9%) | 411 (45.2%) | Not statistically significant |
| Therapy prescription | 234 (19.6%) | 222 (24.4%) | |
| Therapy administration | 376 (31.5%) | 276 (30.4%) | |
§, §§, *, **, *** Standardized Residues (SR) with > or < 2 values and p < 0.05.